Myeloperoxidase gene variation and coronary flow reserve in young healthy men

Journal of Biomedical Science

Volumn 11, Issue 1, 2004, Pages 59-64

  Mäkelä, Riikka ^a   Laaksonen, Reijo ^a,c   Janatuinen, Tuula ^d   Vesalainen, Risto ^e   Nuutila, Pirjo ^d   Jaakkola, Olli ^a,b   Knuuti, Juhani ^d   Lehtimäki, Terho ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Coronary artery blood flow; Endothelial function; Genetics; Myeloperoxidase; Positron emission tomography

Indexed keywords

ADENOSINE; CHOLESTEROL; MYELOPEROXIDASE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; FAMILY HISTORY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPEREMIA; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING;

ADENOSINE; ADULT; CHOLESTEROL; CORONARY CIRCULATION; GENOTYPE; HUMANS; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; PEROXIDASE; PROMOTER REGIONS (GENETICS); REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED; VARIATION (GENETICS);

EID: 0942268177     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000075289     Document Type: Article

References (51)

1. Arcaro G, Zenere BM, Travia D, Zenti MG, Covi G, Lechi A, Muggeo M. Non-invasive detection of early endothelial dysfunction in hypercholesterolaemic subjects. Atherosclerosis 114:247-254;1995.
2. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, Lusis AJ. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107:419-430;2001.
3. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347:5-12;2002.
4. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104:2305-2310;2001.
5. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, Loddenkemper R, Roots I. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 60:644-649;2000.
6. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 96:3378-3383;1997.
7. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444;1994.
8. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 90:808-817;1994.
9. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397;1998.
10. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390;1992.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502;1972.
12. Friese RS, Fullerton DA, McIntyre RC Jr, Rehring TF, Agrafojo J, Banerjee A, Harken AH. NO prevents neutrophil-mediated pulmonary vasomotor dysfunction in acute lung injury. J Surg Res 63:23-28;1996.
13. Granger DN. Ischemia-reperfusion: Mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 6:167-178;1999.
14. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97:1535-1544;1996.
15. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 290:165-172;1993.
16. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99:2075-2081;1997.
17. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: Pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res 85:950-958;1999.
18. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141:1-15;1998.
19. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: Tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 6:145-155;1997.
20. Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, Siest G, Tiret L, Visvikis S. Serum myeloperoxidase concentration in a healthy population: Biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 9:780-786;2001.
21. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, Knuuti J. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 38:561-568;2001.
22. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93:480-489;1980.
23. Kopprasch S, Leonhardt W, Pietzsch J, Kuhne H. Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. Atherosclerosis 136:315-324;1998.
24. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit ? Acta Haematol 104:10-15;2000.
25. Laine H, Raitakari OT, Niinikoski H, Pitkänen OP, Iida H, Viikari J, Nuutila P, Knuuti J. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 32:147-153;1998.
26. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272:3520-3526;1997.
27. Lehtimäki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, Ylä-Herttuala S, Luoma JS, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19:23-27;1999.
28. Leipert B, Becker BF, Gerlach E. Different endothelial mechanisms involved in coronary responses to known vasodilators. Am J Physiol 262:1676-1683;1992.
29. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57:5001-5003;1997.
30. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, Reynolds WF. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78:97-107;1997.
31. Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142:336-339;2001.
32. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, Iglehart JD, Deininger PL, McDonnell DP. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 270:22777-22782;1995.
33. Nuszkowski A, Grabner R, Marsche G, Unbehaun A, Malle E, Heller R. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem 276:14212-14221;2001.
34. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 84:172-176;2003.
35. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420;1996.
36. Pitkänen OP, Nuutila P, Raitakari OT, Porkka K, Iida H, Nuotio I, Ronnemaa T, Viikari J, Taskinen MR, Ehnholm C, Knuuti J. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 99:1678-1684;1999.
37. Pitkänen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H, Lehtimäki TJ, Laine HK, Takala T, Viikari JS, Knuuti J. Coronary flow reserve is reduced in young men with IDDM. Diabetes 47:248-254;1998.
38. Pitkänen OP, Raitakari OT, Niinikoski H, Nuutila P, Iida H, Voipio-Pulkki LM, Härkonen R, Wegelius U, Ronnemaa T, Viikari J, Knuuti J. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 28:1705-1711;1996.
39. Pitkänen OP, Raitakari OT, Ronnemaa T, Niinikoski H, Nuutila P, Iida H, Viikari JS, Knuuti J. Influence of cardiovascular risk status on coronary flow reserve in healthy young men. Am J Cardiol 79:1690-1692;1997.
40. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103:1547-1560;1999.
41. Raitakari OT, Pitkänen OP, Lehtimäki T, Lahdenperä S, Iida H, Ylä-Herttuala S, Luoma J, Mattila K, Nikkari T, Viikari JS, Knuuti J. In vivo low density lipoprotein relates to coronary reactivity in young men. J Am Coll Cardiol 30:97-102;1997.
42. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90:2730-2737;1997.
43. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155:31-41;1999.
44. Reynolds WF, Stegeman CA, Cohen Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 103:154-160;2002.
45. Ross R. Atherosclerosisan inflammatory disease. N Engl J Med 340:115-126;1999.
46. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339:883-887;1992.
47. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 7:53-58;2000.
48. Zhang C, Patel R, Eiserich JP, Zhou F, Kelpke S, Ma W, Parks DA, Darley-Usmar V, White CR. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. Am J Physiol Heart Circ Physiol 281:1469-1475;2001.
49. Zhang C, Reiters C, Eiserich JP, Boersma B, Parks DA, Beckman JS, Barnes S, Kirk M, Baldus S, Darley-Usmar VM, White CR. L-Arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 276:27159-27165;2001.
50. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142;2001.
51. Zhang R, Shen Z, Nauseef WM, Hazen SL. Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase- deficient subjects: Systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood 99:1802-1810;2002.